Tin-halide compounds. IV1. tert-butyltrichlorotin (IV) by Reuter, Hans, Eickmeier, Henning, Puff, Heinrich, Beckermann, Norbert, Hänssgen, Dieter

Get full text

Tin-halide compounds. IV by Reuter, Hans, Eickmeier, Henning, Puff, Heinrich, Beckermann, Norbert, Hänssgen, Dieter

Get full text

Tin-halide compounds. IV. Tert-butyltrichlorotin(IV) by REUTER, Hans, EICKMEIER, Henning, PUFF, Heinrich, BECKERMANN, Norbert, HÄNSSGEN, Dieter

Get full text

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia by Montesinos, Pau, Beckermann, Benjamin M, Catalani, Olivier, Esteve, Jordi, Gamel, Katia, Konopleva, Marina Y, Martinelli, Giovanni, Monnet, Annabelle, Papayannidis, Cristina, Park, Aaron, Récher, Christian, Rodríguez-Veiga, Rebeca, Röllig, Christoph, Vey, Norbert, Wei, Andrew H, Yoon, Sung-Soo, Fenaux, Pierre

Get full text

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial by Konopleva, Marina Y., Röllig, Christoph, Cavenagh, Jamie, Deeren, Dries, Girshova, Larisa, Krauter, Jürgen, Martinelli, Giovanni, Montesinos, Pau, Schäfer, Jonas A., Ottmann, Oliver, Petrini, Mario, Pigneux, Arnaud, Rambaldi, Alessandro, Recher, Christian, Rodriguez-Veiga, Rebeca, Taussig, David, Vey, Norbert, Yoon, Sung-Soo, Ott, Marion, Muehlbauer, Susanne, Beckermann, Benjamin M., Catalani, Olivier, Genevray, Magali, Mundt, Kirsten, Jamois, Candice, Fenaux, Pierre, Wei, Andrew H.

Get full text

Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study by Laufs, Ulrich, Birkenfeld, Andreas L., Fraass, Uwe, Hohenstein, Bernd, Siegert, Carsten, Klotsche, Jens, Steinhagen-Thiessen, Elisabeth, Pittrow, David, Dexl, Stefan, Salmen, Sunnhild, Schettler, Volker J. J., Parhofer, Klaus G.

Get full text